Lv1
82 积分 2022-06-14 加入
Case Series: Effectiveness and Safety of Telitacicept in Chinese Patients With Primary Sjögren's Disease
7天前
已完结
[Recommendations for the diagnosis and treatment of Sjögren's syndrome in China]
15天前
已完结
Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis
18天前
已完结
Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis
22天前
已关闭
Telitacicept use in children with IgA vasculitis nephritis: preliminary observations
26天前
已完结
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure
28天前
已完结
Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept
29天前
已完结
BAFF and APRIL counterregulate susceptibility to inflammation-induced preterm birth
1个月前
已完结
Exploring Telitacicept in a patient with Pemphigus Vulgaris
1个月前
已完结
皖公网安备34019202002308
